Introduction: Burkitt Lymphoma (BL) is an aggressive B- cell malignancy that is highly prevalent in Sub-Saharan Africa (SSA), contributing to 50% of paediatric cancer. In this region where Epstein Barr virus (EBV) is endemic, more than 90% of cases of BL are associated with EBV (EBL). Survival rate for BL in SSA is less than 50%, largely due to late presentation of advanced disease coupled with mis- or delayed diagnosis all of which delays initiation of effective chemo-immunotherapy.
